Jin Matsuyama
Overview
Explore the profile of Jin Matsuyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kawada J, Sakai D, Kimura Y, Hirao M, Nishikawa K, Sugimoto N, et al.
Anticancer Res
. 2025 Mar;
45(3):1077-1085.
PMID: 40037863
Background/aim: Irinotecan is a key drug for patients with advanced gastric cancer. We assessed the efficacy and safety of combination chemotherapy with trastuzumab and irinotecan in patients with advanced human...
2.
Shinkai M, Imano M, Yokokawa M, Tanaka R, Matsuyama J, Shimokawa T, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 39934541
No abstract available.
3.
Shinkai M, Imano M, Yokokawa M, Tanaka R, Matsuyama J, Shimokawa T, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2651-2661.
PMID: 39812918
Background: To improve the prognosis of clinically resectable type 4 or large type 3 gastric cancer (GC), we performed a phase I/II study of neoadjuvant-radiotherapy combined with S-1 plus cisplatin....
4.
Shinkai M, Imano M, Yokokawa M, Matsuyama J, Kimura Y, Shimokawa T, et al.
Med Oncol
. 2024 Dec;
42(1):31.
PMID: 39699794
Purpose The prognosis for type 4 and large type 3 gastric cancer (GC) is extremely poor, especially in elderly patients (≥ 75 years). To improve the prognosis of these types...
5.
Kimura Y, Sugimoto N, Endo S, Kawabata R, Matsuyama J, Takeno A, et al.
Gastric Cancer
. 2024 Nov;
28(1):112-121.
PMID: 39520591
Background: The prognosis of advanced gastric cancer (GC) with extensive lymph node (LN) metastasis treated with surgery alone remains poor. We conducted a multicenter phase II study to evaluate the...
6.
Makino T, Nakai S, Momose K, Yamashita K, Tanaka K, Miyata H, et al.
Esophagus
. 2024 May;
21(3):319-327.
PMID: 38717686
Background: Real-world clinical outcomes of and prognostic factors for nivolumab treatment for esophageal squamous-cell carcinoma (ESCC) remain unclear. This study aimed to evaluate real-world outcomes of nivolumab monotherapy in association...
7.
Sunakawa Y, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, et al.
Oncologist
. 2024 Apr;
29(8):e997-e1002.
PMID: 38581687
Background: This prospective observational study evaluated the real-world effectiveness of nivolumab monotherapy in previously treated advanced gastric cancer (GC). A preplanned 2-year final analysis was performed to confirm survival and...
8.
Saito T, Kurokawa Y, Fujitani K, Kawabata R, Takeno A, Mikami J, et al.
Br J Cancer
. 2024 Feb;
130(7):1157-1165.
PMID: 38326601
Background: No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a...
9.
Nishikawa K, Kimura Y, Kishi K, Inoue K, Matsuyama J, Akamaru Y, et al.
Int J Clin Oncol
. 2024 Jan;
29(3):266-275.
PMID: 38227091
Background: We previously showed that daily nutritional intervention with an oral elemental diet (ED) at 300 kcal/day for 6-8 weeks postoperatively decreased the percentage of body weight loss (%BWL), and...
10.
Kawase T, Imamura H, Kawabata R, Matsuyama J, Nishikawa K, Yanagihara K, et al.
Int J Clin Oncol
. 2024 Jan;
29(2):134-141.
PMID: 38227090
Background: Although there is insufficient evidence for the treatment of older patients with advanced gastric cancer, fluorouracil combined with platinum chemotherapy has been recognized as a standard first-line treatment for...